Coagulation factors evaluation in NIDDM patients

American Journal of Biochemistry and Molecular Biology

Volumn 1, Issue 3, 2011, Pages 244-254

  Mard Soltani, Maysam ^a   Dayer, Mohammad Reza ^b   Ataie, Ghasem ^a   Moazedi, Ahmad Ali ^b   Dayer, Mohammad Saaid ^c   Alavi, Sayed Mohammad Reza ^b  

^a PAYAME NOOR UNIVERSITY   (Iran)

^b SHAHID CHAMRAN UNIVERSITY OF AHVAZ   (Iran)

^c TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Coagulation factors; Common pathway; Hypercoagulable; Intrinsic pathway; NIDDM

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PROTHROMBIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCOAGULABILITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTIAL THROMBOPLASTIN TIME; PROGNOSIS; PROTHROMBIN TIME;

EID: 79955556996     PISSN: 21504210     EISSN: 21504253     Source Type: Journal    
DOI: 10.3923/ajbmb.2011.244.254     Document Type: Article

References (56)

1. Barillari, G., E. Favor, S. Pasca and E. Bigotto, 2009. Coagulation and oxidative stress plasmatic levels in a type 2 diabetes population. Blood Coagul. Fibrinolysis, 20: 290-296.
2. Behnam-Rassouli, M., M.B. Ghayour and N. Ghayour, 2010. Microvascular complications of diabetes. J. Biol. Sci, 10: 411-423.
3. Berliner, J.I., A.C. Rybicki, R.C. Kaplan, E.S. Monrad, R. Freeman and H.H. Billett, 2002. Elevated levels of Factor XI are associated with cardiovascular disease in women. Thrombosis Res., 107: 55-60.
4. Bolaman, Z., F. Kok, G. Kadikoylu, N. Kiyhoglu, E. Guney and A. Akyol, 2007. The changes of coagulation parameters and microvascular complications in diabetes mellitus. Endocrinologist, 17: 196-199.
5. Bonetti, B.O., L.O. Lerman and A. Lerman, 2003. Endothelial dysfunction: A marker ofatherosclerotic risk. Arterioscler. Throm. Vase. Biol., 23: 168-175.
6. Borissoff, B.J.I., S. Heeneman, E. Kilinc, B. Kassak and R. Van Oerle et al., 2010. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation, 122: 821-830.
7. Bots, M.L., B.C. Elwood, J.T. Salonen, A.F. De Concalves and J. Sivenius et al., 2002. Level of fibrinogen and risk of fatal and non-fatal stroke. Eurostork: A collaborative study among research centres in Europe. Epidemiol. Commun. Health., 56: 14-18.
8. Cardigan, R.A., H. McGloin, I.J. Mackie, S.J. Machin and M. Singer, 1999. Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration. Kidney Int., 55: 1568-1574.
9. Carmassi, F., M. Morale, R. Fuccetti, F. De Negri, F. Monzam, R. Navalesi and G. Mariam, 1992. Coagulation and fibrinolytic system impairment in IDDM. Thromb Res., 32: 680-684.
10. Carr, M.E., 2001. Diabetes mellitus: A hypercoagulable state. J. Diabetes Complications, 15: 44-54.
11. Collier, A., A. Rumiey, A.G. Rumley, R.F. John, BL. John, D.O. Gordon and S. Micheal, 1992. Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes, 41: 909-913.
12. Dubrey, S.W., D.R. Reaveley, M. Seed, D.A. Lane and H. Ireland et al., 1994. Risk factors for cardiovascular disease in IDDM: A study of identical twins. Diabetes, 43: 831-835.
13. El-Hagracy, R.S, G.M. Kamal, I.M. Sabry, AA. Saad, N.F.A. El-Ezz and H.A.R. Nasr, 2010. Tissue factor, tissue factor pathway inhibitor and factor VII activity in cardiovascular complicated type2 diabetes mellitus. OMJ, 25: 173-178.
14. El-Khawand, C, J. Jamart, J. Donckier, B. Chatelain, E. Lavenne, M. Moriau and M. Buysschaert,1993. Hemostasis variables in type I diabetic patients without demonstrable vascular complications. Diabetes Care, 16: 1137-1145.
15. Elhadd, T.A., T.A. Abdu, J. Oxtoby, G. Kennedy and M. McLaren et al, 2001. Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency. J. Clin. Endocrinol. Metab., 86: 4223-4232.
16. Eteng, M.U., B.J. Bassey, I.J. Atangwho, G.E. Egbung, E.U. Eyong, B.E. Ebong and A.O. Abolaji, 2008. Biochemical Indices of macrovascular complication in diabetic rat model: Compared effects of Vernonia amygdalina, Catharantus roseus and chlorpropamide. Asian J. Biochem., 3: 228-234.
17. Falati, S., F. Gross, G. Merrill-Skoloff, B.C. Furie and B. Furie, 2002. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat. Med., 8: 1175-1180.
18. Frankel, D.S, J.B. Meigs, J.M. Massaro, B.W.F. Wilson, C.J. ODonnell, R.B. D'Agostmo and G.H. Toiler, 2008. Von willebrand factor, type 2 diabetes mellitus and risk of cardiovascular disease. Circulation, 118: 2533-2539.
19. Hajifathali, A., K. Bahram, B. Aliakbar, R.L. Ghasem and C. Rouzbeh, 2005. Coagulation factor V mutations in iranian patients with venous thrombosis. Bak. J. Biol. Sci., 8: 1272-1274.
20. Hameed, A., S.A. Malik, F. Rabbi, A. Sharif and N. Ahmad et al., 2002. Diabetic complications: Influence of age, sex, family history, duration, glycemic control and obesity. J. Biol. Sci., 2: 710-714.
21. Harris, B.L., D.R. Harvey and B.B. Bliss, 1978. The importance of plasma lipid, glucose, insulin and fibrinogen in femoropopliteal surgery. Br. J. Surg., 65: 197-200.
22. Ibbotson, S.H., D. Walmsley, J.A. Davies and B.J. Grant, 1992. Generation of thrombin activity in relation to factor VIII: C concentrations and vascular complications in type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 35: 863-867.
23. Karami, H., K. Vahidshahi, M. Kosarian, H. Karami and S. Shahmohammadi et al., 2010. Assessment of coagulation state and its related factors in thalassemia intermedia patients referred to thalassemia research center at booali sina hospital sari/IR Iran in 2007. Bak. J. Biol. Sci., 13: 448-451.
24. Kessler, L., M.L. Wiesel, B. Attah, J.M. Mossard, J.B. Cazenave and M. Bmget, 1998. Von willebrand factor in diabetic angiopathy. Diabetes Metab., 24: 327-336.
25. Kluft, C. and J. Jespersen, 2002. Diabetes as a procoagulant condition. Br. J. Diabetes Vascular Dis, 2: 358-362.
26. Koster, T., AD. Blann, E. Briet, J.B. Vandenbroucke and F.R. Rosendaal, 1995. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet., 345: 152-155.
27. Kucharska-Newton, A.M., D.J. Couper, J.S. Fankow, R.J. Brineas and TD. Rea et al., 2009. Hemostasis, inflammation and fatal and nonfatal coronary heart disease. Arteriosclerosis, Thrombosis, Vascular Biol., 29: 2182-2190.
28. Laakso, M. and S. Lehto, 1998. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atherosclerosis, 137: 65-73.
29. Lee, A.J., F.G. Fowkes, A. Rattray, A. Rumley and GD. Lowe, 1996. Haemostatic and rheological factors in intermittent claudication: The influence of smoking and extent of arterial disease. Br. J. Haematol., 92: 226-230.
30. Li, L., T. Sawamura and G. Renier, 2003. Glucose enhances endothelial LOX-1 expression: Role for LOX-1 in glucose-induced human monocyte adhesion to endothelium. Diabetes, 52: 1843-1850.
31. Lip, G.Y. and A. Blann, 1997. Von Willebrand factor: A marker of endothelial dysfunction in vascular disorders? Cardiovasc. Res., 34: 255-265.
32. Lohmann, O, N. Schafer, T. Von Lukowicz, M.A.S. Stein and J. Boren et al., 2009. Atherosclerotic mice exhibit systemic inflammation in peri adventitial and visceral adipose tissue, liver and pancreatic islets. Atherosclerosis, 207: 360-367.
33. Lowe, G.D., M.M. Drummond, A.R. Lorimer, GD. Lowe and M.M. Drummond et al., 1980. Relation between extent of coronary artery disease and blood viscosity. BMJ, 280: 673-674.
34. Lusis, A., 2000. Atherosclerosis. Nature, 407: 233-241.
35. Mackman, N., 2004. Role of tissue factor in hemostasis, thrombosis and vascular development. Arterioscler Thromb Vase. Biol., 24: 1015-1022.
36. Madan, R., B. Gupta, S. Saluja, U.C. Kansra, B.K. Tripathi and B.B. Guliani, 2010. Coagulation profile in diabetes and its association with diabetic microvascular complications. J. Assoc. Bhysicians India, 58: 481-484.
37. Makin, A.J, A.D. Blann, N.A.Y. Chung, S.H. Silverman and G.Y.H. Lip, 2004. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor. Eur. Heart J., 25: 371-376.
38. Meade, T.W, J.A Cooper, Y. Stirling, D.J. Howarth, V. Ruddock and G.J. Miller, 1994. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br. J. Haematol., 88: 601-607.
39. Meade, T.W., S. Mellows, M. Brozovic, G.J. Miller and R.R. Chakrabarti et al, 1986. Haemostatic function and ischaemic heart disease: Brincipal results of the northwick park heart study. Lancet, 2: 533-537.
40. Meigs, J.B., C.J. ODonnell, G.H. Toiler, E.J. Benjamin and OS. Fox et al, 2006. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: The Framingham offspring study. Diabetes, 55: 530-537.
41. Merlo, O, W.A. Wmllemm, M. Redondo, M. Furlan and I. Sulzer et al, 2002. Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease. Atherosclerosis, 161: 261-267.
42. Mmnema, M.C., R.J. Feters, R. De Winter, Y.B.T. Lubbers and S. Barzegar et al, 2000. Activation of clotting factors XI and IX in patients with acute myocardial infarction. Arterioscler Thromb Vase Biol, 20: 2489-2493.
43. Ray, S.A, M.R. Rowley, A. Loh, S.A Talbot, D.H. Bevan, R.S. Taylor and J.A. Dormandy, 1994. Hypercoagulable states in patients with leg ischaemia. Br. J. Surg, 81: 811-814.
44. Reverter, J.L, J.C. Reverter, D. Tassies, F. Rius and J. Monteagudo et al, 1997. Thrombomodulin and induced tissue factor expression on monocytes as marker of diabetic microangiopathy: A prospective study on hemostasis and lipoproteins in insulin dependent diabetes mellitus. Am. J. Hematol, 56: 93-99.
45. Rezaeian, Z, G. Torkaman, F. Nad-ali, R. Ravanbod and A.A. Fourfathollah et al, 2006. Effect of physical fitness on the coagulant activity of healthy young men. Fak. J. Biol. Sci, 9: 2032-2039.
46. Schneider, D.J, 2005. Abnormalities of coagulation, platelet function, and fibrinolysis associated with syndromes of insulin resistance. Coronary Artery Dis, 16: 473-476.
47. Thor, M, A. Yu and J. wedenborg, 2002. Markers of inflammation and hypercoagulability in diabetic and nondiabetic patients with lower extremity ischemia. Thrombosis Res, 105: 379-383.
48. Tripodi, A, A. Branchi, V. Chantarangkul, M. Clerici, G. Merati, A. Artoni and B.M. Mannucci, 2010. Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. J. Thromb Thrombolys, 31: 165-172.
49. Vaidyula, V.R, G.J. Criner, C. Grabianowski and A.K. Rao, 2009. Circulating tissue factor procoagulant activity is elevated in stable moderate to severe chronic obstructive pulmonary disease. Thrombosis Res, 124: 259-261.
50. Voetsch, B. and J. Loscalzo, 2004. Genetic determinants of arterial thrombosis. Arteriosclerosis Thromb. Vase. Biol, 24: 216-229.
51. Wakabayashi, I. and H. Masuda, 2002. Relation of serum sialic acid to blood coagulation activity in type 2 diabetes. Blood Coagulation Fibrinolysis, 13: 691-696.
52. Weiss, C, S. Regele, T. Velich, F. Bartsch and T. Weiss, 2000. Hemostasis and fibrinolysis in patients with intermittent claudication: Effects of prostaglandin El. Brostaglandins, Leukotrienes Essent Fatty Acids, 63: 271-277.
53. Whiteley, W., W.L. Chong, A. Sengupta and P. Sandercock, 2009. Blood markers for the prognosis of ischemic stroke: A systematic review. Stroke, 40: 380-389.
54. Wiseman S., G. Kenchmgton, R. Dam, C.E. Marshall, C.N. McCollum, R.M. Greenhalgh and J.T. Powell, 1989. Influence of smoking and plasma factors on patency of femoropopliteal vein grafts. Br. Med. J., 299: 643-646.
55. Woodburn, K.R., G.D. Lowe, A. Rumley, J. Love and J.G. Pollock, 1995. Relation of haemostatic, fibrinolytic and rheological variables to the angiographic extent of peripheral arterial occlusive disease. Int Angiol., 14: 346-352.
56. Zachary, T. and M.D. Bloomgarden, 2011. Diabetes and cardiovascular disease. Diabetes Care, 34: 24-30.